Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Miebach

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 18, 2005
Enzyme replacement therapy in mucopolysaccharidosis type IE Miebach
International Journal of Clinical Pharmacology and Therapeutics|December 31, 2009
Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disordersE Miebach
Neuropediatrics|August 30, 2000
Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidosesR Boor, E Miebach, K Brühl, et al.
Klinische Monatsblatter Fur Augenheilkunde|March 24, 2010
[Lysosomal storage diseases - update and new therapeutic options]K Schöpfer, E Miebach, M Beck, et al.
Der Orthopade|January 23, 2008
[Mucopolysaccharidoses]B Link, E Miebach, T Vetter, et al.
Journal of Inherited Metabolic Disease|January 7, 2004
Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB studyF Baehner, C Kampmann, C Whybra, et al.
Journal of Inherited Metabolic Disease|January 26, 2006
Cumulative incidence rates of the mucopolysaccharidoses in GermanyF Baehner, C Schmiedeskamp, F Krummenauer, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|February 8, 2003
Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathyC Kampmann, C M Wiethoff, C Martin, et al.
Clinical Genetics|March 18, 2004
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapyC Whybra, C Kampmann, F Krummenauer, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Acta Paediatrica (Oslo, Norway : 1992). Supplement|May 18, 2005
Enzyme replacement therapy in mucopolysaccharidosis type IE Miebach
International Journal of Clinical Pharmacology and Therapeutics|December 31, 2009
Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disordersE Miebach
Neuropediatrics|August 30, 2000
Abnormal somatosensory evoked potentials indicate compressive cervical myelopathy in mucopolysaccharidosesR Boor, E Miebach, K Brühl, et al.
Klinische Monatsblatter Fur Augenheilkunde|March 24, 2010
[Lysosomal storage diseases - update and new therapeutic options]K Schöpfer, E Miebach, M Beck, et al.
Der Orthopade|January 23, 2008
[Mucopolysaccharidoses]B Link, E Miebach, T Vetter, et al.
Journal of Inherited Metabolic Disease|January 7, 2004
Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB studyF Baehner, C Kampmann, C Whybra, et al.
Journal of Inherited Metabolic Disease|January 26, 2006
Cumulative incidence rates of the mucopolysaccharidoses in GermanyF Baehner, C Schmiedeskamp, F Krummenauer, et al.
Acta Paediatrica (Oslo, Norway : 1992). Supplement|February 8, 2003
Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathyC Kampmann, C M Wiethoff, C Martin, et al.
Clinical Genetics|March 18, 2004
The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapyC Whybra, C Kampmann, F Krummenauer, et al.
Pageof 1